Novartis LCZ696: 'New Wonder Drug' OR 'Old Paradigm With Reduced Side Effects'
- Back in 2012, study results, for Novartis’ new drug Serelaxin, for treatment of heart failure, were announced with a good deal of fanfare.
- Like Serelaxin, results for Novartis’ new drug for heart failure, LCZ696, have been announced with a great deal of publicity. The media reports have similarities to those for Serelaxin.
- In March 2014, an FDA committee questioned the design and outcomes of the Serelaxin trial, and unanimously rejected approval of the drug.
- While I believe the case for LCZ696 is far stronger than the Serelaxin case ever was, the title of this article reflects concerns and reservations reflected in the article below.